Intelligo

Private limited company · Lillestrøm

ONCOGENE AS

ActiveTechnical testing and analysis (71.200)

Founded
29 Sep 2020
Business address
Gunnar Randers' vei 12, 2007 Kjeller

The website has not been read for a card yet.

The life line 2020–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 1.2m.

  1. Kapital§ 14
  2. Managing director took office§ 07
  3. Chair took office§ 07
  4. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

ONCOGENE AS is a private limited company in Lillestrøm, founded in 2020, in the industry technical testing and analysis. The chief executive is Morten Bjelke-Holtermann Duesund, and the chair of the board is Morten Bjelke-Holtermann Duesund. In 2025 the company had NOK 1.2m in operating revenue and a net profit of NOK −2.3m. The largest owner is MODUS I AS with 72.0%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 14 Oct 2026

  • Registered as an employer
  • No longer registered as an employer
  • Annual accounts filed 2024 → 2025
  • Kapital

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

None registered

None of the rules apply.The rules are fixed: bankruptcy, missing annual accounts, three years of losses, negative equity and the like. Checked 15 Nov 2026.

Overview

§ 03 Key figures

Revenue NOK 1.2m in 2025

Revenue

NOK 1.2m

+85.4% from 2024

20232025

Operating profit

NOK −2.1m

−1,155.3% from 2024

20232025

Net profit

NOK −2.3m

−4,145.5% from 2024

20232025

Equity

NOK 32k

−97.1% from 2024

20232025

Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Wages and social costs 114%
  • Depreciation 43%
  • Other operating costs 113%
  • Not specified in the source 8%

Costs exceeded revenue: the operating result was NOK −2.1m.

Source: the Register of Company Accounts via areg.no, read 15 Nov 2026

Finances

§ 05 Financial health

Equity ratio 0.5%

RevenueNOK 1.2m Operating margin−177.7% Equity ratio0.5% Revenue growth+85.4%
  • ONCOGENE AS, 2025
  • Industry median, assumed: NOK 2.7m · 6.6% · 50.9% · +4.4%

Equity NOK 32k1% of the assets (NOK 5.9m)

Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 340 companies in 71.200 Technical testing and analysis, not stated by the source.

Finances

§ 06 Accounts

5 years, latest 2025

NOK 1,0002023–25202520242023
Operating revenue1,194644—
Operating profit−2,122201−46
Profit before tax−2,30957−46
Net profit−2,30957−46
Total assets5,9387,5211,330
Equity321,10137
Liabilities5,9066,4201,294

Source: the Register of Company Accounts, read 15 Nov 2026 · All 5 years →

Management and ownership

§ 07 Officers

5 officers now

The board: 3 members

Source: the Brønnøysund Register Centre, read 22 Oct 2026 · All 6 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

None registered

No signature or procuration registered.The Register of Business Enterprises has no provision for the company. Checked 15 Nov 2026.

Management and ownership

§ 09 Owners

3 shareholders · largest 72.0%

OwnerShare
MODUS I AS
72.0%
ECONTO AS
10.0%
MAKRI INVEST AS
5.0%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 3 owners →

Management and ownership

§ 10 Group

None registered

Not a group.No subsidiaries in the shareholder register, and no group accounts. Checked 15 Nov 2026.

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

19 connections

  • Person
  • Company

3 people link ONCOGENE AS to 12 other companies: Morten Bjelke-Holtermann Duesund 7, Ida Christine Filtenborg Hansen 4 and Tore Helge Rismyhr 1.

Source: the Brønnøysund Register Centre, read 22 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

17 since 2020

Events per year

20202026

  • Notices12
  • Register changes3
  • Owners in and out2

Since 2020: 12 announcements, 3 register changes and 2 new and 0 former owners. Most happened in 2024 and 2026.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 15 Nov 2026. Register changes are Intelligo's own observations. · All 17 events →

Events and registers

§ 14 Notices

12, latest 28 Apr 2026

  • Kapital
  • Vedtektsdato
  • Godkjente årsregnskap

Source: The Brønnøysund Register Centre's announcements ↗, read 15 Nov 2026 · All 12 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 21 Oct 2020
  • VATRegistered
  • The Register of Business EnterprisesRegistered 21 Oct 2020
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Tilby genetiske analyser for privatpersoner, forskning og annen næringsvirksomhet, samt bioinformatikk analyse av alle slag for presisjonsmedisin og personalisert terapi, og annet som naturlig faller sammen med dette.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 71.200

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

5 questions

  • Who is the chief executive of ONCOGENE AS?
    Morten Bjelke-Holtermann Duesund, since 2024. § 07
  • Who owns ONCOGENE AS?
    3 shareholders. The largest is MODUS I AS with 72.0%, ECONTO AS with 10.0% and MAKRI INVEST AS with 5.0%. § 09
  • What was the revenue in 2025?
    NOK 1.2m in the company. § 06
  • Where is ONCOGENE AS based?
    Gunnar Randers' vei 12, 2007 Kjeller.
  • When was ONCOGENE AS founded?
    29 Sep 2020, registered in the Register of Business Enterprises 21 Oct 2020. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose